Target intelligence / Profile preview

Envelope glycoprotein Gn and Envelope glycoprotein Gc (Gn and Gc)

Target
Gn and Gc
Molecular classification
Viral envelope glycoprotein, Class II fusion protein (Gc specifically), Other (Gn: surface spike, receptor binding), Other (Gc: fusion protein)
01

Overview

Envelope glycoproteins Gn and Gc are surface-exposed viral proteins that, as heterodimers, form spike complexes essential for virus assembly, structure, and infectivity. The Gn protein serves mainly in receptor recognition and binding, while Gc is a class II fusion protein that undergoes conformational changes to mediate fusion between the viral and endosomal membranes. These proteins assemble into tetrameric spikes and a surface lattice on the viral envelope. Both are derived from a single polyprotein precursor encoded in the viral M segment and cleaved by host signal peptidases. Their surface-exposed regions are highly immunogenic, making them primary targets for neutralizing antibodies and candidate vaccines, but they can evade immunity via conformational shielding, glycosylation, and structural plasticity. Blocking Gn or Gc function prevents viral entry and infection.

Other names
Viral glycoprotein GnViral glycoprotein GcHantavirus glycoprotein GnHantavirus glycoprotein GcPhenuivirus Gn/Gc envelope proteinsM segment glycoprotein Gn/Gc
02

Mechanism of action

Neutralization of viral entry via antibody binding; Inhibition of receptor binding and conformational changes necessary for membrane fusion

03

Biological functions

Virus assemblyVirus buddingHost cell recognition and attachment (primarily Gn)Membrane fusion for viral entry (Gc; fusion loop exposure)Evasion of host immune response
04

Disease associations

Infection (causative for hantavirus, phenuivirus diseases, e.g., severe fever with thrombocytopenia syndrome, hantavirus pulmonary syndrome)
05

Safety considerations

Antibody-dependent enhancement (theoretical for viral glycoprotein-directed therapies)Viral evasion via glycan shielding or escape mutations in glycoproteins
06

Interacting drugs

None currently FDA-approved, but several experimental neutralizing antibodies and vaccine candidates directly interact with Gn/Gc. Several drug and monoclonal antibody designs target conformational epitopes on these glycoproteins.
07

Biomarkers

Serological detection of anti-Gn or anti-Gc antibodies in patient blood (used in diagnostic assays for infection and immunity)

Beyond the preview

Go deeper on Envelope glycoprotein Gn and Envelope glycoprotein Gc (Gn and Gc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envelope glycoprotein Gn and Envelope glycoprotein Gc (Gn and Gc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call